Medical Condition

psoriasis

Total Trials

11

Recruiting Now

11

Trial Phases

Phase 1, Phase 4

ClinicalMetric tracks all active clinical trials for psoriasis sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — psoriasis Clinical Trials

How many clinical trials are currently recruiting for psoriasis?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for psoriasis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for psoriasis?

psoriasis research spans Phase 1 (3 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a psoriasis clinical trial?

Eligibility criteria for psoriasis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 4

Chong Kun Dang Pharmaceutical

View Trial →

NCT04950218

Recruiting

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology

psoriasis

Frequently Asked Questions — psoriasis Clinical Trials

Recruiting Clinical Trials

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Dietary Approach to Mild-to-moderate Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Regulation of Inflammatory Genes in Psoriasis

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Cytokine Expression in Psoriasis Patients with and Without Joint Involvement